Bigul

Jubilant Life Sciences receives ANDA approval for Paroxetine Tablets

Jubilant Life Sciences Ltd has informed BSE regarding a Press Release dated December 01, 2015, titled "Jubilant Life Sciences receives ANDA approval for Paroxetine Tablets".
01-12-2015
Bigul

Exercise of ESOP Stock Options

Jubilant Life Sciences Ltd has informed BSE that 5,560 options under Jubilant Employees Stock Option Plan 2005 (Plan 2005) and 1,76,906 options under JLL Employees Stock Option Plan 2011 (Plan 2011) have been exercised by the option holders.Pursuant to the terms of Plan 2005 and Plan 2011, the Nomination, Remuneration and Compensation Committee of the Company (the Committee) has approved, on November 09, 2015, transfer of 2,04,706 equity...
09-11-2015
Bigul

Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011

Jubilant Stock Holding Pvt Ltd has submitted the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 to BSE
09-11-2015

Jubilant Life plans to raise $200 million

The firm will look to raise the funds by either raising equity or through other instruments such as foreign currency convertible bonds, global depository receipts etc
29-10-2015
Bigul

Outcome of Board Meeting

Jubilant Life Sciences Ltd has informed BSE that the Board of Directors of the Company at its meeting held on October 29, 2015, inter alia, the following decisions have been taken:- The Board has accorded approval for raising funds through issue of Equity / GDRs / ADRs / FCCBs or other equity related instruments upto an amount of USD 200 million [Rs. 1300 crores (approx.)], subject to approval of the shareholders of the Company and other necessary approvals.
29-10-2015
Bigul

Announces Q2 results, Limited Review Report, Results Press Release & Presentation for the Quarter ended September 30, 2015

Jubilant Life Sciences Ltd has announced the following results for the quarter ended September 30, 2015:The Un-Audited Standalone results for the Quarter ended September 30, 2015The Company has posted a net profit of Rs. 509.10 million for the quarter ended September 30, 2015 where as the same was at Rs. 2167.60 million for the quarter ended September 30, 2014. Total Income is Rs. 7458.90 million for the quarter ended September 30,...
29-10-2015
Bigul

Disclosure under Regulation 3(12) of SEBI (Share Based Employee Benefit) Regulations, 2014

Jubilant Life Sciences Ltd has informed BSE that the Jubilant Employees Welfare Trust (the "Trust") had un-appropriated inventory of 29,65,766 equity shares of the Company of Re. 1 each as on October 28, 2014 which was not backed by grant of options.Further, as per the provisions of Jubilant Employees Stock Option Plan 2005 ("Plan 2005") read with the Scheme of Amalgamation and Demerger between the Company, Speciality Molecules Limited, Pace...
28-10-2015
Bigul

Board Meeting on Oct 29, 2015

Jubilant Life Sciences Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on October 29, 2015, inter alia, to consider the proposal to issue securities which may include equity shares and/or instruments or securities convertible into, exchangeable with or otherwise linked to the equity shares of the Company, up to an amount of USD 200 million or Rs. 1300 crores approx.
27-10-2015
Bigul

Q2 results on Oct 29, 2015

Jubilant Life Sciences Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on October 29, 2015, inter-alia, to consider and approve the Unaudited Financial Results of the Company for the quarter ended September 30, 2015 (Q2).Further, as per the Companys Code of Conduct for Prevention of Insider Trading, the Trading Window for dealing in the securities of the Company would remain closed for the Designated...
20-10-2015
Bigul

Jubilant Life Sciences gets USFDA nod for generic version of Maxalt-MLT

The medicine is the generic version of Maxalt-MLT orally-disintegrating, 5 mg and 10 mg tablets of Merck.
20-10-2015
Next Page
Close

Let's Open Free Demat Account